Skip to content

Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization

Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization, A Single Center Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02933892
Acronym
RADIAL-CKD
Enrollment
39
Registered
2016-10-14
Start date
2016-10-31
Completion date
2024-08-30
Last updated
2024-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Chronic Kidney Disease, Heart Disease

Brief summary

The investigators will conduct a randomized controlled trial that aims to compare the incidence of contrast-induced nephropathy between transradial- and transfemoral-access cardiac catheterization.

Detailed description

Cardiac catheterization is a medical procedure used to diagnose and treat heart conditions. Approaching the heart can be done by different access sites: via the femoral artery (transfemoral) or the radial artery (transradial). Transfemoral access (TFA) is the primary mode of arterial access. Several clinical trials have demonstrated the benefit of transradial over transfemoral approach. The primary advantage of transradial approach is a significant reduction of access-site complications. Chronic Kidney Disease (CKD) is a serious condition associated with premature mortality, decreased quality of life, and increased health-care expenditures. ). It is commonly found in patients with diabetes, hypertension, hyperlipidemia, coronary artery disease, or combinations of these risk factors. Coronary artery disease and CKD are often comorbid conditions seen in the cath lab. Cardiac catheterization is a mainstay of diagnosis and treatment for coronary artery disease and 58% of deaths in CKD are related to cardiovascular deaths. Patients with CKD and who undergo a cardiac catheterization are at risk for contrast-induced nephropathy (CIN) due to the dye used during the procedure. The investigators will conduct a randomized controlled trial that aims to compare the incidence of CIN between transradial and transfemoral cardiac catheterization.

Interventions

PROCEDURECardiac Catheterization

Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.

Sponsors

Texas Tech University Health Sciences Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 88 Years
Healthy volunteers
No

Inclusion criteria

1. Patients scheduled to undergo non-emergent cardiac catheterization at University Medical Center Hospital, Lubbock, TX from January 2016 to January 2018. Emergent cardiac catheterizations will be defined as a catheterization scheduled \< 24 hours from a cardiac event. 2. Patients willing to be randomized to TFA or TRA procedure. 3. Patients signed and dated the informed consent agreeing to participate in the study. 4. Patients with chronic kidney disease, defined as eGFR = 15-59mL/min defined by the MDRD formula. (eGFR is a standard of care measurement for all patients undergoing coronary intervention.). 5. Patients ages 18-88 years old.

Exclusion criteria

1. Patients who have previously undergone a coronary artery bypass graft procedure. 2. Patients with prior catheterization within the last 5 years. 3. Women who are pregnant or expect to become pregnant. Pregnancy tests for women of childbearing potential (WOCHP) will be performed as standard of care. 4. Patients with a history of cardiogenic shock. 5. Children (under the age of 18). 6. Medical, geographical, or social factors making study participation impractical, i.e. documented noncompliance, unable to return for follow-ups and lab draws, etc. 7. A positive Allen's Test on the right radial artery. 8. Any condition preventing TRA or TFA access. 9. Contrast used within the previous 3 weeks. 10. Allergy to contrast dye. 11. Inability to successfully access the artery randomized to use.

Design outcomes

Primary

MeasureTime frame
Incidence of CIN3 days
Need for dialysis30 days

Secondary

MeasureTime frame
All cause mortality30 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026